75 results
8-K
EX-10.1
SLNO
Soleno Therapeutics Inc
29 Sep 23
Entry into a Material Definitive Agreement
4:55pm
to be paid by it and any other assessment, fine or penalty levied against it, to the extent that any of the foregoing is due and payable, except … for any such assessment, fine or penalty that is currently being contested in good faith and (iii) has set aside on its books provision reasonably adequate
8-K
EX-1.1
SLNO
Soleno Therapeutics Inc
29 Sep 23
Entry into a Material Definitive Agreement
4:55pm
not reasonably be expected to result in a Material Adverse Effect, no deficiency assessment with respect to a proposed adjustment of the Company’s
424B5
jygx5r0744d6 ltoov
29 Sep 23
Prospectus supplement for primary offering
4:51pm
424B5
ueh2 rysdxmi6ch
27 Sep 23
Prospectus supplement for primary offering
5:26pm
8-K
EX-99.1
1sxfw rqmyte
26 Sep 23
Soleno Therapeutics Announces Positive Statistically Significant Top-line Results from
7:30am
8-K
yv1 5whzi
16 Aug 23
Departure of Directors or Certain Officers
9:00am
8-K
EX-10.1
t2w 1l1tktnsvu2bu3dh
19 Dec 22
Soleno Therapeutics Announces Financing Commitment for up to $60 Million
4:49pm
424B5
ypgqgo5vetpkon9s3jiz
30 Mar 22
Prospectus supplement for primary offering
5:21pm